Regeneron Pharmaceuticals Reports Q2 2026 IPR&D Charge ~$127M

What Happened

• Regeneron Pharmaceuticals, Inc. filed an 8-K on July 6, 2026 reporting that it currently expects an acquired in‑process research and development (IPR&D) charge of approximately $127 million (pre‑tax) for the quarter ended June 30, 2026.
• The company said this charge is expected to reduce both GAAP and non‑GAAP net income per diluted share for Q2 2026 by about $1.00. Results are preliminary, unaudited, and subject to final closing procedures.

Key Details

• Estimated acquired IPR&D charge: ~$127 million (pre‑tax).
• Expected impact on EPS: ~$(1.00) on both GAAP and non‑GAAP net income per diluted share for Q2 2026.
• Charge relates to up‑front and opt‑in payments under collaboration and licensing agreements (may include asset purchases, development milestones, and premiums on equity securities).
• Regeneron does not routinely forecast such charges due to uncertainty in timing and magnitude; actual results may differ.

Why It Matters

• An unexpected $127M IPR&D charge is a one‑time item that lowers reported earnings for the quarter and impacts EPS guidance for both GAAP and company‑reported non‑GAAP measures.
• Because Regeneron also reports non‑GAAP results that exclude certain items, investors should note the company still expects the charge to affect its non‑GAAP EPS in this quarter.
• The filing is preliminary; final quarterly results could change when Regeneron completes its financial close and any additional disclosures.